JP2006528701A - 疾患の治療のためのカテコールブタンの投与のための方法と組成物 - Google Patents

疾患の治療のためのカテコールブタンの投与のための方法と組成物 Download PDF

Info

Publication number
JP2006528701A
JP2006528701A JP2006533316A JP2006533316A JP2006528701A JP 2006528701 A JP2006528701 A JP 2006528701A JP 2006533316 A JP2006533316 A JP 2006533316A JP 2006533316 A JP2006533316 A JP 2006533316A JP 2006528701 A JP2006528701 A JP 2006528701A
Authority
JP
Japan
Prior art keywords
composition
disease
ndga
composition according
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006533316A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006528701A5 (https=
Inventor
ヘラー，ジョナサン
フレイザー，ニール
コリンズ，エイミー・エル・ツイ
Original Assignee
エリモス・ファーマスーティカルズ・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エリモス・ファーマスーティカルズ・エルエルシー filed Critical エリモス・ファーマスーティカルズ・エルエルシー
Publication of JP2006528701A publication Critical patent/JP2006528701A/ja
Publication of JP2006528701A5 publication Critical patent/JP2006528701A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Optics & Photonics (AREA)
  • Psychiatry (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
JP2006533316A 2003-05-20 2004-05-20 疾患の治療のためのカテコールブタンの投与のための方法と組成物 Pending JP2006528701A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US47200803P 2003-05-20 2003-05-20
US47228203P 2003-05-20 2003-05-20
US47214403P 2003-05-20 2003-05-20
US47218803P 2003-05-20 2003-05-20
US47229903P 2003-05-20 2003-05-20
PCT/US2004/016117 WO2004112696A2 (en) 2003-05-20 2004-05-20 Methods and compositions for delivery of catecholic butanes for treatment of diseases

Publications (2)

Publication Number Publication Date
JP2006528701A true JP2006528701A (ja) 2006-12-21
JP2006528701A5 JP2006528701A5 (https=) 2007-07-12

Family

ID=33545640

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006533316A Pending JP2006528701A (ja) 2003-05-20 2004-05-20 疾患の治療のためのカテコールブタンの投与のための方法と組成物
JP2006533343A Pending JP2007500229A (ja) 2003-05-20 2004-05-20 腫瘍の治療のためのカテコールブタンの投与のための方法と組成物
JP2006533314A Pending JP2006528700A (ja) 2003-05-20 2004-05-20 肥満の治療のためのカテコールブタンの投与のための方法と組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2006533343A Pending JP2007500229A (ja) 2003-05-20 2004-05-20 腫瘍の治療のためのカテコールブタンの投与のための方法と組成物
JP2006533314A Pending JP2006528700A (ja) 2003-05-20 2004-05-20 肥満の治療のためのカテコールブタンの投与のための方法と組成物

Country Status (6)

Country Link
US (1) US20060141047A1 (https=)
EP (3) EP1631269A4 (https=)
JP (3) JP2006528701A (https=)
CN (1) CN103585136A (https=)
AU (3) AU2004249123A1 (https=)
WO (3) WO2005007080A2 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10214983A1 (de) 2002-04-04 2004-04-08 TransMIT Gesellschaft für Technologietransfer mbH Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen
AU2003253214A1 (en) * 2002-09-09 2004-03-29 Koninklijke Philips Electronics N.V. Method of signal reconstruction, imaging device and computer program product
WO2006079021A2 (en) * 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
CA2595606C (en) * 2005-01-27 2014-12-16 Erimos Pharmaceuticals Llc Oral formulations for delivery of catecholic butanes including ndga compounds
CN101325944B (zh) * 2005-10-11 2013-01-16 耶路撒冷希伯来大学伊萨姆研究开发公司 用于鼻部给药的组合物
US20070128289A1 (en) * 2005-12-07 2007-06-07 Zhao Jonathon Z Nano-and/or micro-particulate formulations for local injection-based treatment of vascular diseases
FR2896694A1 (fr) 2006-01-30 2007-08-03 Genfit S A Utilisation d'inhibiteurs de 15-lipoxygenases dans le traitement du syndrome metabolique
US7863157B2 (en) * 2006-03-17 2011-01-04 Silicon Genesis Corporation Method and structure for fabricating solar cells using a layer transfer process
DE102006013531A1 (de) * 2006-03-24 2007-09-27 Lts Lohmann Therapie-Systeme Ag Polylactid-Nanopartikel
GB2441499B (en) * 2006-09-08 2011-09-14 Jasin El Sammadoni Slimming Spray
US9067875B2 (en) 2006-10-02 2015-06-30 Erimos Pharmaceuticals Llc Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
EP2076252B1 (en) 2006-10-02 2014-04-02 Erimos Pharmaceuticals LLC Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
EP1970051A1 (en) * 2007-03-14 2008-09-17 Merz Pharma GmbH & Co.KGaA Use of an aqueous micro-emulsion for the preparation of a formulation for the treatment of adipose diseases
EP2039352A1 (en) * 2007-09-18 2009-03-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Aqueous-core lipid nanocapsules for encapsulating hydrophilic and/or lipophilic molecules
US8962015B2 (en) 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
US9145453B2 (en) * 2007-09-28 2015-09-29 Sdg, Inc. Orally bioavailable lipid-based constructs
US8846053B2 (en) * 2008-09-26 2014-09-30 Sdg, Inc. Orally bioavailable lipid-based constructs
US20100080773A1 (en) 2008-09-26 2010-04-01 Sdg, Inc. Orally Bioavailable Lipid-Based Constructs
US9161943B2 (en) 2007-12-31 2015-10-20 Industrial Technology Research Institute Sustained release composition and manufacturing method thereof
US20100093872A1 (en) * 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
WO2010102065A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives
WO2010111132A2 (en) 2009-03-27 2010-09-30 Bend Research, Inc. Spray-drying process
DE102009031274A1 (de) 2009-06-30 2011-01-13 Justus-Liebig-Universität Giessen Liposomen zur pulmonalen Applikation
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins DELAYED RELEASE OF THERAPIES IN A PART OF THE EYE
US9084976B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
PT2611530T (pt) 2010-09-03 2019-05-09 Bend Res Inc Aparelho de secagem por pulverização e métodos de utilização do mesmo
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
JP5222917B2 (ja) * 2010-09-21 2013-06-26 財團法人工業技術研究院 徐放性組成物およびその製造方法
WO2012040502A1 (en) 2010-09-24 2012-03-29 Bend Research, Inc. High-temperature spray drying process and apparatus
WO2012109363A2 (en) 2011-02-08 2012-08-16 The Johns Hopkins University Mucus penetrating gene carriers
US9084727B2 (en) 2011-05-10 2015-07-21 Bend Research, Inc. Methods and compositions for maintaining active agents in intra-articular spaces
US20140329913A1 (en) * 2011-12-14 2014-11-06 The Johns Hopkins University Nanoparticles with enhanced mucosal penetration or decreased inflammation
JP6255038B2 (ja) * 2013-02-26 2017-12-27 トリアクト セラピューティクス，インク． 癌治療
WO2015175545A1 (en) 2014-05-12 2015-11-19 The Johns Hopkins University Highly stable biodegradable gene vector platforms for overcoming biological barriers
JP6953414B2 (ja) * 2016-01-20 2021-10-27 フラリー パウダーズ エルエルシーＦｌｕｒｒｙ Ｐｏｗｄｅｒｓ，Ｌｌｃ 親油性成分を含む吸入に好適な分散性の噴霧乾燥粉末を製造する方法
WO2018169954A1 (en) 2017-03-13 2018-09-20 Sdg, Inc. Lipid-based nanoparticles with enhanced stability
US11077173B2 (en) 2017-03-13 2021-08-03 Sdg, Inc. Lipid-based nanoparticles and methods using same
US12496279B2 (en) 2019-04-11 2025-12-16 The Johns Hopkins University Nanoparticles for drug delivery to brain
CN114831938B (zh) * 2022-05-24 2023-04-18 郑州大学第一附属医院 一种包载阿托伐他汀钙的聚合物胶束、制剂及制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708964A (en) * 1984-02-09 1987-11-24 Chemex Pharmaceuticals Lipoxygenase inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3934034A (en) * 1972-08-21 1976-01-20 Sandoz, Inc. Hydroxy substituted diphenylalkyls for treatment of lipidemia
US4098908A (en) * 1975-10-20 1978-07-04 Sandoz, Inc. Phenoxyphenyl pyridyl ketones and derivatives and their use as hypolepidemic agents
US5008294A (en) * 1985-02-11 1991-04-16 Chemex Pharmaceuticals, Inc. Methods of treating tumors with compositions of catecholic butanes
US4774229A (en) * 1982-04-05 1988-09-27 Chemex Pharmaceuticals, Inc. Modification of plant extracts from zygophyllaceae and pharmaceutical use therefor
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
US4880637A (en) * 1985-02-11 1989-11-14 Chemex Pharmaceuticals, Inc. Compositions of catecholic butanes with zinc
WO1988003800A1 (en) * 1986-11-19 1988-06-02 Chemex Pharmaceuticals, Inc. Lipoxygenase inhibitors
WO1995005156A1 (en) * 1993-08-17 1995-02-23 Schering-Plough Healthcare Products, Inc. Compositions for treating corns, calluses and warts
US6365787B1 (en) * 1994-09-30 2002-04-02 The Johns Hopkins University Compounds for the suppression of HIV TAT transactivation
AU698619B2 (en) * 1995-06-07 1998-11-05 University Of Southern California Method for reducing or preventing post-surgical adhesion formation using 5-lipoxygenase inhibitors
US5837252A (en) * 1996-07-01 1998-11-17 Larreacorp, Ltd. Nontoxic extract of Larrea tridentata and method of making same
US5827898A (en) * 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes
AU8759298A (en) * 1997-10-06 1999-04-27 Shaman Pharmaceuticals, Inc. Use of nordihydroguaiaretic acid to lower serum triglycerides, blood pressure and to treat syndrome
US6576660B1 (en) * 1997-10-31 2003-06-10 Arch Development Corporation Methods and compositions for regulation of 5-α-reductase activity
US6214874B1 (en) * 1999-10-15 2001-04-10 John Hopkins University Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N
US6608108B2 (en) * 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives
US6545019B2 (en) * 2000-07-13 2003-04-08 Bristol-Myers Squibb Company Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders
US7365099B2 (en) * 2001-05-31 2008-04-29 Wisconsin Alumni Research Foundation Animal body fat control
SK287806B6 (sk) * 2001-06-28 2011-10-04 Pfizer Products Inc. Triamid-substituované indoly, benzofurány a benzotiofény ako inhibítory mikrozómového proteínu prenášajúceho triglyceridu (MTP) a/alebo sekrécie apolipoproteínu B (Apo B)
WO2003103583A2 (en) * 2002-06-10 2003-12-18 Oklahoma Medical Research Foundation A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708964A (en) * 1984-02-09 1987-11-24 Chemex Pharmaceuticals Lipoxygenase inhibitors

Also Published As

Publication number Publication date
AU2004249124A1 (en) 2004-12-29
US20060141047A1 (en) 2006-06-29
JP2006528700A (ja) 2006-12-21
EP1631271A2 (en) 2006-03-08
WO2004112695A3 (en) 2005-04-07
WO2005007080A2 (en) 2005-01-27
AU2004249123A1 (en) 2004-12-29
EP1631269A4 (en) 2007-09-12
EP1631270A4 (en) 2007-11-14
EP1631269A2 (en) 2006-03-08
WO2005007080A3 (en) 2005-07-07
CN103585136A (zh) 2014-02-19
EP1631271A4 (en) 2007-12-12
WO2004112696A3 (en) 2005-03-31
WO2004112695A2 (en) 2004-12-29
EP1631270A2 (en) 2006-03-08
WO2004112695B1 (en) 2005-05-26
WO2004112696A2 (en) 2004-12-29
AU2004257575A1 (en) 2005-01-27
JP2007500229A (ja) 2007-01-11

Similar Documents

Publication Publication Date Title
JP2006528701A (ja) 疾患の治療のためのカテコールブタンの投与のための方法と組成物
US20110135711A1 (en) Methods and Compositions for Delivery of Catecholic Butanes for Treatment of Tumors
Ramalho et al. Nanotechnology to improve the Alzheimer’s disease therapy with natural compounds
Pulivendala et al. Inhalation of sustained release microparticles for the targeted treatment of respiratory diseases
US8784881B2 (en) Liposomal curcumin for treatment of diseases
CN104105507B (zh) 增强粘膜渗透或减少炎症的纳米粒子
US20060141029A1 (en) Methods and compositions for delivery of catecholic butanes for treatment of diseases
JP2002518432A (ja) 吸入器から放出される大多孔性粒子
KR20090006062A (ko) 인플루엔자 바이러스 감염의 치료 방법
US20190046446A1 (en) Apo-e modified lipid nanoparticles for drug delivery to targeted tissues and therapeutic methods
Sachin et al. Solid lipid nanoparticles–preparation, applications, characterization, uses in various cancer therapies: a review
Sou Curcumin towards nanomedicine
Abdoullateef et al. Nanoencapsulation of general anaesthetics
Alle et al. Niosomes: A Smart Drug Carrier Synthesis, Properties and Applications
Kotb et al. Lipid-Based Nanocarriers for Brain Delivery of Bioactives in the Treatment of Neurodegenerative Disorders
Vyas et al. Solid-lipid nanocarriers (SLNs)-based drug delivery for treating various pulmonary diseases
Boddu et al. Nanocarrier systems for lung drug delivery
HK1195003A (en) Methods and compositions for delivery of catecholic butanes for treatment of tumors
Rahimpour et al. Lipidic Micro‐and Nano‐Carriers for Pulmonary Drug Delivery—A State‐of‐the‐Art Review
Gaspar et al. General introduction-Particle engineering by nanoparticle microencapsulation for pulmonary delivery
da Silva et al. Nanostructured Drug Carriers for Nose-to-Brain Drug Delivery: A Novel Approach for Neurological Disorders
da Conceição et al. The use of nanocarriers for drug delivery through the blood-brain barrier.
Gaber et al. In vivo pharmacodynamics of lactoferrin-coupled lipid nanocarriers for lung carcinoma: intravenous versus powder for inhalation
Kotb et al. 13 Lipid-Based Nanocarriers for Brain
CN1849115A (zh) 用于治疗肿瘤的邻苯二酚丁烷的释放的方法和组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070521

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110107

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110207

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110307

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110314

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110721